In total, 13% of patients had mutations in genes significantly associated with increased risk for PC across a range of sensitivity analyses (ATM, BRCA1, BRCA2, CDKN2A, MSH6, PALB2, and TP53). The gene discussed is BRCA2; the disease is pachyonychia congenita.